DK1135158T3 - Forbedrede vacciner baseret på kimære immunglobulin-E-peptider - Google Patents

Forbedrede vacciner baseret på kimære immunglobulin-E-peptider

Info

Publication number
DK1135158T3
DK1135158T3 DK99963705T DK99963705T DK1135158T3 DK 1135158 T3 DK1135158 T3 DK 1135158T3 DK 99963705 T DK99963705 T DK 99963705T DK 99963705 T DK99963705 T DK 99963705T DK 1135158 T3 DK1135158 T3 DK 1135158T3
Authority
DK
Denmark
Prior art keywords
immunogenic polypeptides
methods
mammal
ige
nucleic acid
Prior art date
Application number
DK99963705T
Other languages
Danish (da)
English (en)
Inventor
Lars T Hellman
Original Assignee
Resistentia Pharmaceuticals Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resistentia Pharmaceuticals Ab filed Critical Resistentia Pharmaceuticals Ab
Application granted granted Critical
Publication of DK1135158T3 publication Critical patent/DK1135158T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK99963705T 1998-11-02 1999-10-21 Forbedrede vacciner baseret på kimære immunglobulin-E-peptider DK1135158T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10665298P 1998-11-02 1998-11-02
US09/401,636 US6913749B2 (en) 1998-11-02 1999-09-22 Immunogenic polypeptides for inducing anti-self IgE responses

Publications (1)

Publication Number Publication Date
DK1135158T3 true DK1135158T3 (da) 2006-05-15

Family

ID=26803871

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99963705T DK1135158T3 (da) 1998-11-02 1999-10-21 Forbedrede vacciner baseret på kimære immunglobulin-E-peptider

Country Status (18)

Country Link
US (3) US6913749B2 (xx)
EP (1) EP1135158B1 (xx)
JP (2) JP4205861B2 (xx)
KR (1) KR100559918B1 (xx)
AT (1) ATE314087T1 (xx)
AU (1) AU771889B2 (xx)
CA (1) CA2348756A1 (xx)
DE (1) DE69929240T2 (xx)
DK (1) DK1135158T3 (xx)
ES (1) ES2255325T3 (xx)
HK (1) HK1042844A1 (xx)
HU (1) HUP0105392A3 (xx)
IL (1) IL142582A0 (xx)
NO (1) NO20012135L (xx)
NZ (1) NZ511079A (xx)
PL (1) PL348611A1 (xx)
PT (1) PT1135158E (xx)
WO (1) WO2000025722A2 (xx)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7658101A (en) * 2000-07-28 2002-02-13 Cytos Biotechnology Ag Compositions for inducing self-specific anti-ige antibodies and uses thereof
EP2361635A3 (en) * 2000-08-30 2011-09-14 Pfizer Products Inc. Anti IgE vaccines
US20040156838A1 (en) * 2000-09-06 2004-08-12 Steen Klysner Method for down-regulating ige
PL206976B1 (pl) 2001-02-20 2010-10-29 Ortho Mcneil Pharm Inc Sposoby wytwarzania zawiesiny CD8⁺ do stosowania w leczeniu podmiotu z rakiem lub czerniakiem, sposób produkcji nie występującej naturalnie komórki i nie występująca naturalnie linia komórkowa
US20040071671A1 (en) 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
JP2005516581A (ja) * 2001-05-15 2005-06-09 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 自己免疫およびアレルギー疾患を処置するための非−腫瘍抗原に特異的な細胞傷害性リンパ球を生産するためのエクス−ビボプライミング
JP2003047482A (ja) * 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性IgEワクチン
EP1504102A2 (en) * 2002-05-21 2005-02-09 Resistentia Pharmaceuticals AB Chimeric ige polypeptides and host cells
ES2316780T3 (es) * 2002-09-05 2009-04-16 Resistentia Pharmaceuticals Ab Vacunas contra alergia.
US20080118524A1 (en) * 2006-10-20 2008-05-22 Stefan Persson Anti-IgE Vaccines
WO2008153761A1 (en) * 2007-05-23 2008-12-18 Mastcell Pharmaceuticals, Inc. Methods
WO2009142772A2 (en) 2008-05-23 2009-11-26 Mastcell Pharmaceuticals, Inc. Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
SG186611A1 (en) 2008-12-09 2013-01-30 Pfizer Vaccines Llc Ige ch3 peptide vaccine
CA2800774A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
US9187553B2 (en) * 2012-01-25 2015-11-17 Swey-Shen Chen Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold
WO2013156054A1 (en) * 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
JP5918851B2 (ja) * 2012-06-18 2016-05-18 日本全薬工業株式会社 IgEペプチドワクチン
AU2017221425A1 (en) 2016-02-16 2018-08-23 Regeneron Pharmaceuticals, Inc. Non-human animals having a mutant kynureninase gene

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698201A (en) 1973-05-07 1997-12-16 The Ohio State University Method for treatment of antigenically modified polypeptides
US4767842A (en) 1973-05-07 1988-08-30 The Ohio State University Antigenic modification of polypeptides
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4483793A (en) 1982-10-04 1984-11-20 The Regents Of The University Of California Dimeric oligopeptides as heptenic epitopic sites for hepatitis
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4782137A (en) 1984-01-24 1988-11-01 Immunex Corporation Synthesis of protein with an identification peptide, and hybrid polypeptide incorporating same
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5175385A (en) 1987-09-03 1992-12-29 Ohio University/Edison Animal Biotechnolgy Center Virus-resistant transgenic mice
GB8727045D0 (en) 1987-11-19 1987-12-23 Research Corp Ltd Immunoglobulin e competitor
DE122006000007I1 (de) 1987-12-31 2006-04-27 Tanox Biosystems Inc Antigene epitope, die sich ausschlisslich auf ige-tragenden B-Lymphocyten befinden.
US5254671A (en) * 1990-04-27 1993-10-19 Tanox Biosystems, Inc. Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル. モリソン,シェリー ドメイン‐変性不変部を有する抗体
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
GB8910263D0 (en) 1989-05-04 1989-06-21 Ciba Geigy Ag Monoclonal antibodies specific for an immunoglobulin isotype
US5955076A (en) * 1989-06-15 1999-09-21 Peptide Therapeutics Limited Immunoactive peptides and antibodies and their use in anti-allergy treatment
GB8913737D0 (en) 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment
WO1991001146A1 (en) 1989-07-14 1991-02-07 Praxis Biologics, Inc. Cytokine and hormone carriers for conjugate vaccines
US5733553A (en) 1989-09-29 1998-03-31 Talwar; Gursaran Prasad Recombinant birth control vaccine
JP3449712B2 (ja) 1990-01-23 2003-09-22 タノックス バイオシステムズ インコーポレイテッド ヒトε免疫グロブリン固定ペプチドの細胞外部分及びそれに特異的な抗体
GB2246780B (en) * 1990-05-25 1994-04-27 Nat Res Dev Immunodiagnostic assay for rheumatoid arthritis
US5196197A (en) 1990-08-29 1993-03-23 National Institute Of Immunology Reversible fertility control for prevention of pregnancy in females
JPH06504438A (ja) * 1990-12-13 1994-05-26 イミュネックス・コーポレーション 白血病抑制因子受容体
SE9102808L (sv) 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
US5837686A (en) * 1991-11-25 1998-11-17 Peptide Therapeutics Limited Peptides and antibodies for treatment of rheumatoid arthritis
WO1994005698A1 (en) 1992-09-01 1994-03-17 United Nations Industrial Development Organization Peptide showing cross-reactivity with the anti-hepatitis b surface antigen antiserum
AU5361794A (en) 1992-10-14 1994-05-09 Board Of Trustees Of The Leland Stanford Junior University Enhancement of b cell lymphoma tumor resistance using idiotype/cytokine conjugates
US5762931A (en) 1992-12-31 1998-06-09 National Institute Of Immunology Anti-cancer utility of HCG vaccines
US5532142A (en) * 1993-02-12 1996-07-02 Board Of Regents, The University Of Texas System Method of isolation and purification of fusion polypeptides
US5552537A (en) * 1993-03-24 1996-09-03 The Regents Of The University Of California IgE isoforms and methods of use
US5501855A (en) 1993-09-02 1996-03-26 Talwar; Gursaran P. Neem oil as a male contraceptive
DK96493D0 (da) 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
US5874085A (en) 1993-11-10 1999-02-23 Henry M. Jackson Foundation For The Advancement Of Military Medicine Vaccine for enhanced production of IgA antibodies
FR2715304B1 (fr) 1994-01-26 1996-04-26 Merieux Serums Vaccins Pasteur Vaccin anti-allergique.
WO1995026365A1 (en) 1994-03-28 1995-10-05 United Biomedical, Inc. Synthetic peptide based immunogens for the treatment of allergy
US5651981A (en) * 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
CA2203165A1 (en) 1994-10-25 1996-05-02 United Biomedical, Inc. Synthetic ige membrane anchor peptide immunogens for the treatment of allergy
GB9422294D0 (en) * 1994-11-04 1994-12-21 Peptide Therapeutics Ltd Peptides for anti-allergy treatment
US6949244B1 (en) 1995-12-20 2005-09-27 The Board Of Trustees Of The University Of Kentucky Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
JPH08333390A (ja) 1995-04-07 1996-12-17 Hoechst Japan Ltd ペプチド及びそれからなる自己免疫疾患治療剤
EP0839155B1 (en) * 1995-07-17 2004-10-13 Medivir UK Ltd CYSTEINE PROTEASE INHIBITORS FOR USE IN TREATMENT OF IgE MEDIATED ALLERGIC DISEASES
ZA966075B (en) 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
RU2193413C2 (ru) 1996-03-01 2002-11-27 Новартис Аг Пептидные иммуногены для вакцинации и лечения аллергии
EP0917570A2 (en) 1996-08-05 1999-05-26 The President And Fellows Of Harvard College Mhc binding peptide oligomers and methods of use
SK285639B6 (sk) 1997-04-15 2007-05-03 Pharmexa A/S Modifikovaná ľudská TNFalfa molekula, DNA kódujúce takéto TNFalfa molekuly, spôsob výroby modifikovanej ľudskej TNFalfa molekuly, vakcíny obsahujúce modifikované TNFalfa molekuly a DNA a ich použitie
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
CA2302554C (en) 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
WO1999041369A2 (en) 1998-02-11 1999-08-19 Maxygen, Inc. Genetic vaccine vector engineering
US6299875B1 (en) 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
TWI227241B (en) 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
HUP0103976A3 (en) 1998-10-05 2008-04-28 Pharmexa As Novel methods for therapeutic vaccination
NZ512456A (en) 1998-11-30 2003-10-31 Cytos Biotechnology Ag Ordered molecular presentation of antigens
GB9908533D0 (en) 1999-04-14 1999-06-09 Novartis Ag Organic compounds
CN1355846A (zh) 1999-04-23 2002-06-26 法麦克萨有限公司 用于下调节白细胞介素5活性的方法
AU7658101A (en) 2000-07-28 2002-02-13 Cytos Biotechnology Ag Compositions for inducing self-specific anti-ige antibodies and uses thereof
US20040156838A1 (en) 2000-09-06 2004-08-12 Steen Klysner Method for down-regulating ige
CN1541266A (zh) 2001-06-15 2004-10-27 唐诚公司 用于治疗过敏症及哮喘病的Fcε融合蛋白

Also Published As

Publication number Publication date
DE69929240D1 (de) 2006-02-02
EP1135158A2 (en) 2001-09-26
ES2255325T3 (es) 2006-06-16
AU771889B2 (en) 2004-04-08
AU2008100A (en) 2000-05-22
KR100559918B1 (ko) 2006-03-13
HUP0105392A2 (hu) 2002-04-29
JP4205861B2 (ja) 2009-01-07
JP2006068015A (ja) 2006-03-16
WO2000025722A2 (en) 2000-05-11
US20010038843A1 (en) 2001-11-08
US7459158B2 (en) 2008-12-02
JP4188353B2 (ja) 2008-11-26
NZ511079A (en) 2003-08-29
JP2002531064A (ja) 2002-09-24
US6913749B2 (en) 2005-07-05
PL348611A1 (en) 2002-06-03
HK1042844A1 (en) 2002-08-30
EP1135158B1 (en) 2005-12-28
IL142582A0 (en) 2002-03-10
KR20010089364A (ko) 2001-10-06
CA2348756A1 (en) 2000-05-11
US20030031663A1 (en) 2003-02-13
ATE314087T1 (de) 2006-01-15
NO20012135L (no) 2001-06-25
PT1135158E (pt) 2006-05-31
HUP0105392A3 (en) 2008-04-28
NO20012135D0 (no) 2001-04-30
WO2000025722A3 (en) 2000-10-12
DE69929240T2 (de) 2006-08-31
US20040076625A1 (en) 2004-04-22

Similar Documents

Publication Publication Date Title
DK1135158T3 (da) Forbedrede vacciner baseret på kimære immunglobulin-E-peptider
NO20210499A1 (no) Humanisert, glykoomkonstruert Type II anti-CD20 antistoff og anvendelse derav, samt vertscelle og farmasøytisk sammensetning
CY1121353T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις
CY1122505T1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
CR9236A (es) Moleculas de union al antigeno que fijan eger, vectores que las codifican y usos de las mismas
DK1798288T3 (da) Humane Toll-lignende receptorproteiner, relaterede reagenser og fremgangsmåder
BR0113112A (pt) Anticorpos, de integrina antidual, composições, métodos e usos
SG153874A1 (en) Neutralizing epitope-based growth enhancing vaccine
WO2000073430A3 (de) Vakzine gegen konformationsabhängige antigene sowie gegen antigene, die keine oder nicht ausschliesslich proteine oder peptide sind
DK1167389T3 (da) Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf
DK0500659T3 (da) Monoklonale antistoffer.
TR200102034T2 (tr) Anti kanser aşılaması için antikorların kullanılması
NO20052714D0 (no) Fremgangsmater og materialer for behandling av inflammatoriske tilstander
NO20053363L (no) Malrettede enkle epitoper.
BR0009781A (pt) Anticorpos antiidiotìpicos contra anticorpos que inibem a ligação de imunoglobulina e ao seu receptor de alta afinidade
EP1621209A3 (en) Vaccines based on domains of chimeric immunoglobulin E peptides
Skea et al. Adhesion-mediated enhancement of the adjuvant activity of alum
WO2004000238A3 (en) Utilization of mhc class ii binding motifs in immunization to produce immune serum, monoclonal antibodies and vaccines
Lou et al. Destruction of zona pellucida of ovulated oocytes by anti-ZP3 antibodies: a potential mechanism of ZP-based contraceptive vaccine
Elbashir Detection of antibody response with immunoglobulin-binding bacterial proteins and generation of monoclonal antibodies to the growth hormone receptor.
EA200500943A1 (ru) Направленное действие на еденичные эпитопы
MY155265A (en) Anti-dual integrin antibodies, compositions, methods and uses